Manufacturing Enterprise "Academpharm"
https://academpharm.by/
220141 Minsk, Academician Kuprevich str. 5/3
https://academpharm.by/
220141 Minsk, Academician Kuprevich str. 5/3
The drug Etoricoxib
COUNTRY OF ORIGIN
IDENTIFIER
BO6848PUBLISHED
2023-05-14LAST UPDATE
2023-05-18DEADLINE
Linked profile in other language
Responsible
Natalia Safronova
+375 17 268 6364
production@academpharm.by
+375 17 268 6364
production@academpharm.by
Summary
The manufacturing enterprise "Academpharm" offers consumers the drug Etoricoxib for fast and long-term pain relief in diseases of the joints under a manufacturing agreement and is looking for partners to conclude a distribution services agreement.
Description
The composition of the drug -
one tablet contains: active substance: etoricoxib 30 mg, 60 mg, 90 mg or 120 mg;
excipients: microcrystalline cellulose, croscarmellose sodium, magnesium stearate, anhydrous calcium hydrogen phosphate; shell composition: hypromellose, titanium dioxide (E171), triacetin, lactose monohydrate.
Indications for use -
- to relieve symptoms in osteoarthritis (OA), rheumatoid arthritis (RA), ankylosing spondylitis, as well as to relieve pain and signs of inflammation in acute gouty arthritis.
- for the short-term treatment of pain of moderate intensity due to dental surgery.
- the decision to prescribe a selective COX-2 inhibitor should be based on an assessment of all individual risks for the patient.
The characteristics of the drug, instructions for patients and specialists can be found here (in Russian).
one tablet contains: active substance: etoricoxib 30 mg, 60 mg, 90 mg or 120 mg;
excipients: microcrystalline cellulose, croscarmellose sodium, magnesium stearate, anhydrous calcium hydrogen phosphate; shell composition: hypromellose, titanium dioxide (E171), triacetin, lactose monohydrate.
Indications for use -
- to relieve symptoms in osteoarthritis (OA), rheumatoid arthritis (RA), ankylosing spondylitis, as well as to relieve pain and signs of inflammation in acute gouty arthritis.
- for the short-term treatment of pain of moderate intensity due to dental surgery.
- the decision to prescribe a selective COX-2 inhibitor should be based on an assessment of all individual risks for the patient.
The characteristics of the drug, instructions for patients and specialists can be found here (in Russian).
Advantages and Innovations
- The effect is achieved after 24 minutes.
- Bioavailability - 100% (no need for injections).
- The duration of action is up to 24 hours.
- Reception: 1 time per day.
- The maximum concentration in the blood is 1 hour after ingestion.
- Effective for acute and chronic pain.
- Bioavailability - 100% (no need for injections).
- The duration of action is up to 24 hours.
- Reception: 1 time per day.
- The maximum concentration in the blood is 1 hour after ingestion.
- Effective for acute and chronic pain.
Stage of development
Already on the market
Funding source
State budged
Internal
Internal
IPR status
Exclusive rights
Secret know-how
Secret know-how
Sector group
BioChemTech
Healthcare
Healthcare
Organization information
Type
R&D institution
Year established
2009
NACE keywords
C.21.10 - Manufacture of basic pharmaceutical products
C.21.20 - Manufacture of pharmaceutical preparations
M.72.11 - Research and experimental development on biotechnology
M.74.90 - Other professional, scientific and technical activities n.e.c.
Q.86.90 - Other human health activities
C.21.20 - Manufacture of pharmaceutical preparations
M.72.11 - Research and experimental development on biotechnology
M.74.90 - Other professional, scientific and technical activities n.e.c.
Q.86.90 - Other human health activities
Turnover (in EUR)
10-20M
Already engaged in transnational cooperation
Yes
Additional comments
ACADEMPHARM is a dynamically developing science-intensive state pharmaceutical enterprise.
Activities:
- laboratory pharmaceutical research;
- industrial production of medicines and other pharmaceutical products, vitamin, vitamin-mineral and metabolic complexes, nutraceuticals;
- contract pharmaceutical production.
The state enterprise "AKADEMPHARM" has national certificates of GMP (good manufacturing practice) for the production of all forms of output of its own products.
The company has implemented and operates a pharmaceutical quality system developed in accordance with the requirements of national standards TKP 030-2017 (33050) "good manufacturing practice" and international requirements.
The pharmaceutical quality system includes good manufacturing practice, quality control and quality risk management, is fully documented and its effectiveness is monitored. All parts of the quality system are provided with competent personnel, a sufficient number of appropriate premises, equipment and facilities.
As part of the quality system, the enterprise has a quality assurance department and a quality control department, including:
- physical and chemical laboratory;
- microbiological laboratory;
- group of controllers.
The quality control department of the enterprise is accredited for compliance with GOST ISO / IEC 17025-2019.
Attestat_18.09.2020-pdf-min (2)
A multi-stage quality control system ensures incoming control of raw materials and materials, control of the production process and quality control of manufactured medicines.
Modern laboratory equipment, methods used, validation of quality control methods and production processes, as well as high professionalism of specialists guarantee the quality of products.
Further control of products is carried out during the entire shelf life of archival medicinal products of any series. Functioning system for drug safety monitoring and pharmacovigilance.
The state enterprise "AKADEMPHARM" guarantees the conformity of the manufactured products to their purpose and the requirements of registration documents, minimizing the risks for patients associated with the safety, quality and efficacy of manufactured medicines.
Activities:
- laboratory pharmaceutical research;
- industrial production of medicines and other pharmaceutical products, vitamin, vitamin-mineral and metabolic complexes, nutraceuticals;
- contract pharmaceutical production.
The state enterprise "AKADEMPHARM" has national certificates of GMP (good manufacturing practice) for the production of all forms of output of its own products.
The company has implemented and operates a pharmaceutical quality system developed in accordance with the requirements of national standards TKP 030-2017 (33050) "good manufacturing practice" and international requirements.
The pharmaceutical quality system includes good manufacturing practice, quality control and quality risk management, is fully documented and its effectiveness is monitored. All parts of the quality system are provided with competent personnel, a sufficient number of appropriate premises, equipment and facilities.
As part of the quality system, the enterprise has a quality assurance department and a quality control department, including:
- physical and chemical laboratory;
- microbiological laboratory;
- group of controllers.
The quality control department of the enterprise is accredited for compliance with GOST ISO / IEC 17025-2019.
Attestat_18.09.2020-pdf-min (2)
A multi-stage quality control system ensures incoming control of raw materials and materials, control of the production process and quality control of manufactured medicines.
Modern laboratory equipment, methods used, validation of quality control methods and production processes, as well as high professionalism of specialists guarantee the quality of products.
Further control of products is carried out during the entire shelf life of archival medicinal products of any series. Functioning system for drug safety monitoring and pharmacovigilance.
The state enterprise "AKADEMPHARM" guarantees the conformity of the manufactured products to their purpose and the requirements of registration documents, minimizing the risks for patients associated with the safety, quality and efficacy of manufactured medicines.
Languages spoken
Russian
Information about partnership
Type of partnership considered
Distribution services agreement
Manufacturing agreement
Manufacturing agreement
Type and role of partner sought
Consumers interested in purchasing the drug Etoricoxib for rapid and long-term pain relief in diseases of the joints under a manufacturing agreement.
Partners interested in purchasing the drug Etoricoxib for rapid and long-term pain relief in diseases of the joints under a distribution services agreement.
Partners interested in purchasing the drug Etoricoxib for rapid and long-term pain relief in diseases of the joints under a distribution services agreement.
Type and size of partner sought
> 500
251-500
SME 51-250
SME 11-50
SME <= 10
R&D Institution
University
251-500
SME 51-250
SME 11-50
SME <= 10
R&D Institution
University
Attachments
Views: 1077
Statistics since 14.05.2023 10:06:58
Statistics since 14.05.2023 10:06:58